Janux Therapeutics Inc (JANX) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC Enrollment ongoing for JANX007 and JANX008 Update on...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities